{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:40:45Z","timestamp":1790044845360,"version":"4.0.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012350","name":"British Liver Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","award":["MCCC-FCH-13-U"],"award-info":[{"award-number":["MCCC-FCH-13-U"]}],"id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary sclerosing cholangitis (PSC) is a rare bile duct and liver disease which can considerably impact quality of life (QoL). As part of a project developing a measure of QoL for people with PSC, we conducted a systematic review with four review questions. The first of these questions overlaps with a recently published systematic review, so this paper reports on the last three of our initial four questions: (A) How does QoL in PSC compare with other groups?, (B) Which attributes\/factors are associated with impaired QoL in PSC?, (C) Which interventions are effective in improving QoL in people with PSC?.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched five databases from inception to 1 November 2020 and assessed the methodological quality of included studies using standard checklists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 28 studies: 17 for (A), ten for (B), and nine for (C). Limited evidence was found for all review questions, with few studies included in each comparison, and small sample sizes. The limited evidence available indicated poorer QoL for people with PSC compared with healthy controls, but findings were mixed for comparisons with the general population. QoL outcomes in PSC were comparable to other chronic conditions. Itch, pain, jaundice, severity of inflammatory bowel disease, liver cirrhosis, and large-duct PSC were all associated with impaired QoL. No associations were found between QoL and PSC severity measured with surrogate markers of disease progression or one of three prognostic scoring systems. No interventions were found to improve QoL outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The limited findings from included studies suggest that markers of disease progression used in clinical trials may not reflect the experiences of people with PSC. This highlights the importance for clinical research studies to assess QoL alongside clinical and laboratory-based outcomes. A valid and responsive PSC-specific measure of QoL, to adequately capture all issues of importance to people with PSC, would therefore be helpful for clinical research studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12955-021-01739-3","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T18:02:41Z","timestamp":1616263361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Quality of life in primary sclerosing cholangitis: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-8976","authenticated-orcid":false,"given":"Elena","family":"Marcus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paddy","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Krooupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Vivat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"issue":"6","key":"1739_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol. 2017;67(6):1298\u2013323.","journal-title":"J Hepatol"},{"issue":"12","key":"1739_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMra1506330","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375(12):1161\u201370.","journal-title":"N Engl J Med"},{"issue":"12","key":"1739_CR3","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/ibd.22938","volume":"18","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, van Erpecum KJ, van Nieuwkerk KMJ, Drenth JPH, Poen AC, Witteman BJM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2270\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1739_CR4","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BWM, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045\u201355.","journal-title":"Hepatology"},{"issue":"5","key":"1739_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME, American College of G. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110(5):646\u201359 (quiz 60).","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1739_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356\u201378.","journal-title":"Gut"},{"issue":"8","key":"1739_CR7","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weismuller","year":"2017","unstructured":"Weismuller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152(8):1975\u201384.","journal-title":"Gastroenterology"},{"issue":"2","key":"1739_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.cgh.2017.09.062","volume":"16","author":"GJ Webb","year":"2018","unstructured":"Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, et al. Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. Clin Gastroenterol Hepatol. 2018;16(2):278-87e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1739_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/apt.13154","volume":"41","author":"JE Eaton","year":"2015","unstructured":"Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, de Andrade M, et al. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):980\u201390.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1739_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/flgastro-2017-100815","volume":"8","author":"K Arndtz","year":"2017","unstructured":"Arndtz K, Hirschfield GM. Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterol. 2017;8(4):260\u20136.","journal-title":"Frontline Gastroenterol"},{"issue":"6","key":"1739_CR11","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s10620-015-4013-1","volume":"61","author":"AC Cheung","year":"2016","unstructured":"Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci. 2016;61(6):1692\u20139.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"1739_CR12","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1111\/liv.12775","volume":"35","author":"J Haapamaki","year":"2015","unstructured":"Haapamaki J, Tenca A, Sintonen H, Barner-Rasmussen N, Farkkila MA. Health-related quality of life among patients with primary sclerosing cholangitis. Liver Int. 2015;35(9):2194\u2013201.","journal-title":"Liver Int"},{"issue":"3","key":"1739_CR13","doi-asserted-by":"publisher","first-page":"e025045","DOI":"10.1136\/bmjopen-2018-025045","volume":"9","author":"KS Gurusamy","year":"2019","unstructured":"Gurusamy KS, Walmsley M, Davidson BR, Frier C, Fuller B, Madden A, et al. Top research priorities in liver and gallbladder disorders in the UK. BMJ Open. 2019;9(3):e025045.","journal-title":"BMJ Open"},{"issue":"2","key":"1739_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/hep.28128","volume":"63","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Corpechot C, Pares A, Hirschfield GM. Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology. 2016;63(2):644\u201359.","journal-title":"Hepatology"},{"issue":"1","key":"1739_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","volume":"12","author":"T Morel","year":"2017","unstructured":"Morel T, Cano SJ. Measuring what matters to rare disease patients\u2014reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12(1):171.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"1739_CR16","first-page":"11","volume":"35","author":"V Tothova","year":"2014","unstructured":"Tothova V, Bartlova S, Dolak F, Kaas J, Kimmer D, Manhalova J, et al. Quality of life in patients with chronic diseases. Neuro Endocrinol Lett. 2014;35(Suppl 1):11\u20138.","journal-title":"Neuro Endocrinol Lett"},{"issue":"3","key":"1739_CR17","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4081\/hpr.2013.932","volume":"1","author":"K Megari","year":"2013","unstructured":"Megari K. Quality of life in chronic disease patients. Health Psychol Res. 2013;1(3):e27.","journal-title":"Health Psychol Res"},{"key":"1739_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hep.29775","volume":"68","author":"K Arndtz","year":"2018","unstructured":"Arndtz K, Hirschfield GM. Quality of life and primary sclerosing cholangitis: THE business of defining what counts. Hepatology. 2018;68:16\u20138.","journal-title":"Hepatology"},{"key":"1739_CR19","unstructured":"Marcus E. Developing and pre-testing a measure of quality of life for people with primary sclerosing cholangitis (PSC) in the UK [Unpublished doctoral thesis]. London: University College London; 2020. https:\/\/discovery.ucl.ac.uk\/id\/eprint\/10108246\/. Accessed 14 Feb 2021."},{"issue":"4","key":"1739_CR20","first-page":"CD011343","volume":"2017","author":"F Saffioti","year":"2017","unstructured":"Saffioti F, Gurusamy KS, Hawkins N, Toon CD, Tsochatzis E, Davidson BR, et al. Pharmacological interventions for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2017;2017(4):CD011343.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1739_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jfma.2016.05.006","volume":"115","author":"XY Jin","year":"2016","unstructured":"Jin XY, Khan TM. Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review. J Formos Med Assoc. 2016;115(9):689\u2013702.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1739_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12955-018-0951-6","volume":"16","author":"F Isa","year":"2018","unstructured":"Isa F, Turner GM, Kaur G, Kyte D, Slade A, Pankhurst T, et al. Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review. Health Qual Life Out. 2018;16(1):133.","journal-title":"Health Qual Life Out"},{"issue":"10","key":"1739_CR23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep4.1567","volume":"4","author":"HP Kim","year":"2020","unstructured":"Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, et al. A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Commun. 2020;4(10):1502\u201315.","journal-title":"Hepatol Commun"},{"issue":"3","key":"1739_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/liv.13591","volume":"38","author":"K Zakharia","year":"2018","unstructured":"Zakharia K, Tabibian A, Lindor KD, Tabibian JH. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver Int. 2018;38(3):399\u2013411.","journal-title":"Liver Int"},{"issue":"1","key":"1739_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0038-1676099","volume":"39","author":"V Ranieri","year":"2019","unstructured":"Ranieri V, McKay K, Walmsley M, Senior R, Thorburn D, Kennedy E. Primary sclerosing cholangitis and psychological wellbeing: a scoping review. Semin Liver Dis. 2019;39(1):104\u201310.","journal-title":"Semin Liver Dis"},{"key":"1739_CR26","unstructured":"Marcus E, Vivat B, Stone P, Krooupa A, Thorburn D. Quality of life in primary sclerosing cholangitis: assessment tools, comparisons with other conditions, impacts and interventions. 2017:PROSPERO CRD42017071729. http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD."},{"issue":"3","key":"1739_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/07357909309024860","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Investig. 1993;11(3):327\u201336.","journal-title":"Cancer Investig"},{"key":"1739_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj-Brit Med J. 2011;343:d5928.","journal-title":"Bmj-Brit Med J"},{"key":"1739_CR29","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2013. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"12","key":"1739_CR30","doi-asserted-by":"publisher","first-page":"e011458","DOI":"10.1136\/bmjopen-2016-011458","volume":"6","author":"MJ Downes","year":"2016","unstructured":"Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.","journal-title":"BMJ Open"},{"issue":"7308","key":"1739_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","volume":"323","author":"R Harbour","year":"2001","unstructured":"Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334\u20136.","journal-title":"BMJ"},{"issue":"7","key":"1739_CR32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.cgh.2012.01.025","volume":"10","author":"M Benito de Valle","year":"2012","unstructured":"Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, Kalaitzakis E. Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10(7):769-75e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1739_CR33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11136-015-1161-x","volume":"25","author":"E Kalaitzakis","year":"2016","unstructured":"Kalaitzakis E, Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, et al. Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Qual Life Res. 2016;25(4):947\u201357.","journal-title":"Qual Life Res"},{"issue":"4","key":"1739_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.surg.2005.07.014","volume":"138","author":"E Gorgun","year":"2005","unstructured":"Gorgun E, Remzi FH, Manilich E, Preen M, Shen B, Fazio VW. Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study. Surgery. 2005;138(4):631\u20137 (discussion 7\u20139).","journal-title":"Surgery"},{"issue":"3","key":"1739_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ibd.21051","volume":"16","author":"AN Ananthakrishnan","year":"2010","unstructured":"Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, et al. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflamm Bowel Dis. 2010;16(3):494\u2013500.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"1739_CR36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.lts.2003.09.012","volume":"9","author":"L Longworth","year":"2003","unstructured":"Longworth L, Young T, Buxton MJ, Ratcliffe J, Neuberger J, Burroughs A, et al. Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups. Liver Transplant. 2003;9(12):1295\u2013307.","journal-title":"Liver Transplant"},{"key":"1739_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00365521.2020.1725106","volume":"55","author":"M Vannas","year":"2020","unstructured":"Vannas M, Farkkila M, Sintonen H, Aberg F, Isoniemi H. Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2020;55:1\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"1739_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1399-0012.2012.01597.x","volume":"26","author":"F \u00c5berg","year":"2012","unstructured":"\u00c5berg F, H\u00f6ckerstedt K, Roine RP, Sintonen H, Isoniemi H. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant. 2012;26(5):729\u201335.","journal-title":"Clin Transplant"},{"issue":"10","key":"1739_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/00365520410003434","volume":"39","author":"E Bjornsson","year":"2004","unstructured":"Bjornsson E, Simren M, Olsson R, Chapman RW. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2004;39(10):961\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1739_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jhep.2007.01.036","volume":"46","author":"E van Os","year":"2007","unstructured":"van Os E, van den Broek WW, Mulder PGH, ter Borg PCJ, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007;46(6):1099\u2013103.","journal-title":"J Hepatol"},{"issue":"5","key":"1739_CR41","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/liv.12709","volume":"35","author":"JK Dyson","year":"2015","unstructured":"Dyson JK, Elsharkawy AM, Lamb CA, Al-Rifai A, Newton JL, Jones DE, et al. Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver Int. 2015;35(5):1633\u201341.","journal-title":"Liver Int"},{"issue":"4","key":"1739_CR42","doi-asserted-by":"publisher","first-page":"e0176264","DOI":"10.1371\/journal.pone.0176264","volume":"12","author":"A Kempinska-Podhorodecka","year":"2017","unstructured":"Kempinska-Podhorodecka A, Milkiewicz M, Jablonski D, Milkiewicz P, Wunsch E. ApaI polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. PLoS ONE. 2017;12(4):e0176264.","journal-title":"PLoS ONE"},{"issue":"9","key":"1739_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/qjmed\/hcp091","volume":"102","author":"DEJ Jones","year":"2009","unstructured":"Jones DEJ, Gray JC, Newton J. Perceived fatigue is comparable between different disease groups. QJM. 2009;102(9):617\u201324.","journal-title":"QJM"},{"issue":"4","key":"1739_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-2893.2010.01292.x","volume":"18","author":"HL Tillmann","year":"2011","unstructured":"Tillmann HL, Wiese M, Braun Y, Wiegand J, Tenckhoff S, Mossner J, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepatitis. 2011;18(4):252\u201361.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"1739_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1572-0241.2000.01774.x","volume":"95","author":"ZM Younossi","year":"2000","unstructured":"Younossi ZM, Kiwi ML, Boparai N, Price LL, Guyatt G. Cholestatic liver diseases and health-related quality of life. Am J Gastroenterol. 2000;95(2):497\u2013502.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1739_CR46","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/liv.12730","volume":"35","author":"J Raszeja-Wyszomirska","year":"2015","unstructured":"Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, Rigopoulou EI, Bogdanos D, Milkiewicz P. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver Int. 2015;35(6):1764\u201371.","journal-title":"Liver Int"},{"key":"1739_CR47","doi-asserted-by":"publisher","first-page":"30847","DOI":"10.1038\/srep30847","volume":"6","author":"E Wunsch","year":"2016","unstructured":"Wunsch E, Krawczyk M, Milkiewicz M, Trottier J, Barbier O, Neurath MF, et al. Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases. Sci Rep. 2016;6:30847.","journal-title":"Sci Rep"},{"issue":"10","key":"1739_CR48","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/0895-4356(91)90010-7","volume":"44","author":"RE Tarter","year":"1991","unstructured":"Tarter RE, Switala JA, Arria A, Van Thiel DH. Impact of liver disease on daily living in transplantation candidates. J Clin Epidemiol. 1991;44(10):1079\u201383.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"1739_CR49","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75(7):688\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1739_CR50","doi-asserted-by":"publisher","first-page":"e25539","DOI":"10.5812\/hepatmon.25539","volume":"15","author":"J Raszeja-Wyszomirska","year":"2015","unstructured":"Raszeja-Wyszomirska J, Kucharski R, Zygmunt M, Safranow K, Miazgowski T. The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis. Hepat Mon. 2015;15(4):e25539.","journal-title":"Hepat Mon"},{"issue":"12","key":"1739_CR51","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1097\/MEG.0000000000000223","volume":"26","author":"DN Gotthardt","year":"2014","unstructured":"Gotthardt DN, Rupp C, Bruhin M, Schellberg D, Weiss KH, Stefan R, et al. Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2014;26(12):1374\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"1739_CR52","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1136\/gut.2005.065862","volume":"54","author":"A Jacoby","year":"2005","unstructured":"Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11):1622\u20139.","journal-title":"Gut"},{"issue":"8","key":"1739_CR53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646\u20139.","journal-title":"Br J Surg"},{"issue":"9","key":"1739_CR54","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1055\/s-0030-1255527","volume":"42","author":"CY Ponsioen","year":"2010","unstructured":"Ponsioen CY, Reitsma JB, Boberg KM, Aabakken L, Rauws EA, Schrumpf E. Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy. 2010;42(9):742\u20137.","journal-title":"Endoscopy"},{"issue":"3","key":"1739_CR55","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","volume":"155","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen CY, Arnelo U, Bergquist A, Rauws EA, Paulsen V, Cantu P, et al. No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis. Gastroenterology. 2018;155(3):752\u20139.","journal-title":"Gastroenterology"},{"issue":"7","key":"1739_CR56","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.crohns.2013.12.007","volume":"8","author":"M Pavlides","year":"2014","unstructured":"Pavlides M, Cleland J, Rahman M, Christian A, Doyle J, Gaunt R, et al. Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. J Crohns Colitis. 2014;8(7):662\u201370.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1739_CR57","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464\u201372.","journal-title":"Gastroenterology"},{"issue":"5","key":"1739_CR58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","volume":"42","author":"DW Hommes","year":"2008","unstructured":"Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"1739_CR59","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Farkkila M, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549\u201358.","journal-title":"J Hepatol"},{"issue":"6","key":"1739_CR60","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther. 2013;37(6):604\u201312.","journal-title":"Aliment Pharmacol Ther"},{"key":"1739_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-230X-4-13","volume":"4","author":"PC ter Borg","year":"2004","unstructured":"ter Borg PC, van Os E, van den Broek WW, Hansen BE, van Buuren HR. Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol. 2004;4:13.","journal-title":"BMC Gastroenterol"},{"issue":"1 Supplement","key":"1739_CR62","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/S0618-8278(19)30267-1","volume":"70","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Ling L, Hudgens S, Kim KH, Hirschfield G, DePaoli A, et al. Effect of NGM282, an FGF19 analogue, on pruritus in patients with primary sclerosing cholangitis: analysis of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial. J Hepatol. 2019;70(1 Supplement):e151.","journal-title":"J Hepatol"},{"issue":"4","key":"1739_CR63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour S, Nasiri-Toosi M, Khalili H, Daryani NE, Taromlou MKN, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis. 2016;25(4):457\u201364.","journal-title":"J Gastrointest Liver Dis"},{"issue":"3","key":"1739_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/apt.12581","volume":"39","author":"TH Karlsen","year":"2014","unstructured":"Karlsen TH, Vesterhus M, Boberg KM. Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Aliment Pharmacol Ther. 2014;39(3):282\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1739_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"5","key":"1739_CR66","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/07853890109002086","volume":"33","author":"H Sintonen","year":"2001","unstructured":"Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med. 2001;33(5):328\u201336.","journal-title":"Ann Med"},{"issue":"1","key":"1739_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5009\/gnl16510","volume":"12","author":"C Palmela","year":"2018","unstructured":"Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH. Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver. 2018;12(1):17\u201329.","journal-title":"Gut Liver"},{"issue":"7","key":"1739_CR68","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cgh.2018.04.047","volume":"17","author":"A Kuo","year":"2019","unstructured":"Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL. Characteristics and outcomes reported by patients with primary sclerosing cholangitis through an online registry. Clin Gastroenterol Hepatol. 2019;17(7):1372\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4 Pt B","key":"1739_CR69","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.bbadis.2017.08.015","volume":"1864","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen CY. Endpoints in the design of clinical trials for primary sclerosing cholangitis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1410\u20134.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"8","key":"1739_CR70","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s11136-016-1248-z","volume":"25","author":"WO Chu","year":"2016","unstructured":"Chu WO, Dialla PO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, et al. Determinants of quality of life among long-term breast cancer survivors. Qual Life Res. 2016;25(8):1981\u201390.","journal-title":"Qual Life Res"},{"issue":"3","key":"1739_CR71","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/hep.28963","volume":"65","author":"EM de Vries","year":"2017","unstructured":"de Vries EM, de Krijger M, Farkkila M, Arola J, Schirmacher P, Gotthardt D, et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology. 2017;65(3):907\u201319.","journal-title":"Hepatology"},{"key":"1739_CR72","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/1751-2980.12788","volume":"20","author":"JB Maurice","year":"2019","unstructured":"Maurice JB, Thorburn D. Precision medicine in primary sclerosing cholangitis. J Dig Dis. 2019;20:346\u201356.","journal-title":"J Dig Dis"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-021-01739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-021-01739-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-021-01739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T19:09:49Z","timestamp":1616267389000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-021-01739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1739"],"URL":"https:\/\/doi.org\/10.1186\/s12955-021-01739-3","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}